4.0 Review

Targeted therapies in breast cancer: New challenges to fight against resistance

Journal

WORLD JOURNAL OF CLINICAL ONCOLOGY
Volume 8, Issue 2, Pages 120-134

Publisher

BAISHIDENG PUBLISHING GROUP INC
DOI: 10.5306/wjco.v8.i2.120

Keywords

Breast cancers; Resistance; Human epidermal growth factor receptor 2; Angiogenesis; Triple negative; Immune tolerance

Categories

Funding

  1. French Association for Cancer Research (ARC)
  2. Fondation de France
  3. French National Institute for Cancer Research (INCA)
  4. Fondation Estee Lauder (Pink Ribbon Award)
  5. Roche France and Cordon de Vie Monaco

Ask authors/readers for more resources

Breast cancer is the most common type of cancer found in women and today represents a significant challenge to public health. With the latest breakthroughs in molecular biology and immunotherapy, very specific targeted therapies have been tailored to the specific pathophysiology of different types of breast cancers. These recent developments have contributed to a more efficient and specific treatment protocol in breast cancer patients. However, the main challenge to be further investigated still remains the emergence of therapeutic resistance mechanisms, which develop soon after the onset of therapy and need urgent attention and further elucidation. What are the recent emerging molecular resistance mechanisms in breast cancer targeted therapy and what are the best strategies to apply in order to circumvent this important obstacle? The main scope of this review is to provide a thorough update of recent developments in the field and discuss future prospects for preventing resistance mechanisms in the quest to increase overall survival of patients suffering from the disease.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.0
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available